Disclosed is a polynucleotide having at least 15 contiguous bases in the base sequence of SEQ ID NO:26 and including the base sequence of SEQ ID NO:27. Also disclosed is siRNA produced based on the polynucleotide. By means of this, a cancer cell-specific molecular-targeted therapy, which successfully controls the function of WT1, can be realized.